PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PACIRA BIOSCIENCES, INC. (PCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 90.77 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 52.52K shares, a 395.96% increase year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 38.25K shares, a 264.85% increase year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 22.12K shares, a 57.33% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 181.12K shares.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 224.31K shares, a 23.20% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 292.06K shares, a 15.88% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 252.03K shares, a 122.05% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 113.51K shares, a 59.20% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 52.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 90.77K shares 10-Q · filed 2026-08-04 | 112.89K shares derived: sum of 3 quarters · filed 2026-08-04 | 294.01K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 38.25K shares 10-Q · filed 2026-04-30 | 60.37K shares derived: sum of 2 quarters · filed 2026-04-30 | 241.49K shares derived: sum of 3 quarters · filed 2026-04-30 | 252.08K shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 22.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 203.24K shares derived: sum of 2 quarters · filed 2026-02-26 | 213.83K shares derived: sum of 3 quarters · filed 2026-02-26 | 224.31K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 181.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 191.71K shares derived: sum of 2 quarters · filed 2025-11-06 | 202.19K shares 10-Q · filed 2025-11-06 | 254.02K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 10.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 21.07K shares 10-Q · filed 2025-08-05 | 72.90K shares derived: sum of 3 quarters · filed 2025-08-05 | -226.61K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 10.48K shares 10-Q · filed 2025-05-08 | 62.31K shares derived: sum of 2 quarters · filed 2025-05-08 | -237.20K shares derived: sum of 3 quarters · filed 2025-05-08 | 147.15K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 51.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -247.68K shares derived: sum of 2 quarters · filed 2025-02-27 | 136.66K shares derived: sum of 3 quarters · filed 2025-02-27 | 292.06K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | -299.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 84.83K shares derived: sum of 2 quarters · filed 2024-11-06 | 240.23K shares 10-Q · filed 2024-11-06 | 297.02K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 384.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 539.74K shares 10-Q · filed 2024-07-30 | 596.53K shares derived: sum of 3 quarters · filed 2024-07-30 | 684.85K shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 155.40K shares 10-Q · filed 2024-05-07 | 212.18K shares derived: sum of 2 quarters · filed 2024-05-07 | 300.50K shares derived: sum of 3 quarters · filed 2024-05-07 | 379.60K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 56.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 145.11K shares derived: sum of 2 quarters · filed 2024-02-29 | 224.20K shares derived: sum of 3 quarters · filed 2024-02-29 | 252.03K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 88.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 167.41K shares derived: sum of 2 quarters · filed 2023-11-02 | 195.25K shares 10-Q · filed 2023-11-02 | 219.99K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | 79.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 106.93K shares 10-Q · filed 2023-08-02 | 131.67K shares derived: sum of 3 quarters · filed 2024-02-29 | 166.22K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | 27.83K shares 10-Q · filed 2023-05-03 | 52.57K shares derived: sum of 2 quarters · filed 2024-02-29 | 87.13K shares derived: sum of 3 quarters · filed 2024-02-29 | 107.81K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | 24.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 59.29K shares derived: sum of 2 quarters · filed 2024-02-29 | 79.97K shares derived: sum of 3 quarters · filed 2024-02-29 | 113.51K shares 10-K · filed 2024-02-29 |
| 2022-09-30 | 34.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 55.23K shares derived: sum of 2 quarters · filed 2022-11-03 | 88.77K shares 10-Q · filed 2022-11-03 | 128.13K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 20.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 54.22K shares 10-Q · filed 2022-08-03 | 93.58K shares derived: sum of 3 quarters · filed 2024-02-29 | 138.26K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 33.53K shares 10-Q · filed 2022-05-04 | 72.90K shares derived: sum of 2 quarters · filed 2024-02-29 | 117.58K shares derived: sum of 3 quarters · filed 2024-02-29 | 215.50K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 39.37K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 84.05K shares derived: sum of 2 quarters · filed 2024-02-29 | 181.97K shares derived: sum of 3 quarters · filed 2024-02-29 | 278.23K shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 44.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 142.60K shares derived: sum of 2 quarters · filed 2021-11-03 | 238.87K shares 10-Q · filed 2021-11-03 | 262.32K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 97.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 194.18K shares 10-Q · filed 2021-08-03 | 217.64K shares derived: sum of 3 quarters · filed 2023-02-28 | 470.15K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 96.27K shares 10-Q · filed 2021-05-04 | 119.72K shares derived: sum of 2 quarters · filed 2023-02-28 | 372.24K shares derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | 23.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 275.97K shares derived: sum of 2 quarters · filed 2023-02-28 | 426.93K shares 10-K · filed 2023-02-28 | |
| 2020-09-30 | 252.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 403.47K shares 10-Q · filed 2020-10-30 | ||
| 2020-06-30 | 150.95K shares 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |